Lineage Cell Therapeutics Inc. (LCTX)

Business: Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally.

IPO Date: 06-Mar-1992

CEO, Pres & Director: Mr. Brian M. Culley M.A., M.B.A.

Chief Financial Officer: Mr. Kevin Leon Cook

Listing: NYSE: LCTX

Country: United States

Headquarters: Carlsbad, CA

Website: https://www.lineagecell.com

Market cap: $244.41 Mln

Revenue (TTM): $7.08 Mln

Earnings (TTM): $-48.69 Mln

Cash: $79.94 Mln

Total Debt: $2.56 Mln

Insider's Holding: 4.67%

Liquidity: Low

52 Week range: $1.10 - 3.00

Shares outstanding: 169,727,008

10 Years Aggregate:

• CFO: $-311.57 Mln
• EBITDA: $-338.92 Mln
• Net Profit: $-256.73 Mln